A Study to Evaluate the Efficacy and Safety of AK120 in Subjects With Moderate to Severe Atopic Dermatitis

Exclusion Criteria

• •1. Acute onset of AD within 4 weeks before drug administration.
• •2. The accompany disease have been assessed by the investigators during screening period as unsuitable for participation in this study.
• •3. Any history or symptoms of malignant tumors in any organ within 5 years prior to screening, regardless of whether treatment has been received and whether there are signs of recurrence or metastasis
• •4. Have a known or suspected history of immunosuppressive diseases, including a history of invasive infections.
• •5. Having undergone or planned major surgery within 4 weeks prior to drug administration, or unable to fully recover from surgery prior to drug administration.
• •6. any medical or psychological condition that puts subjects at risk or may affect the study results assessed by investigators.